Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor.

In the present study, the role of BRCA1 in ligand-dependent androgen receptor (AR) signaling was assessed. In transfected prostate and breast cancer cell lines, BRCA1 enhanced AR-dependent transactivation of a probasin-derived reporter gene. The effects of BRCA1 were mediated through the NH2-terminal activation function (AF-1) of the receptor. Cotransfection of p160 coactivators markedly potentiated BRCA1-mediated enhancement of AR signaling. In addition, BRCA1 was shown to interact physically with both the AR and the p160 coactivator, glucocorticoid receptor interacting protein 1. These findings suggest that BRCA1 may directly modulate AR signaling and, therefore, may have implications regarding the proliferation of normal and malignant androgen-regulated tissues.

[1]  O. Manor,et al.  The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. , 1999, American journal of human genetics.

[2]  P. Meltzer,et al.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.

[3]  G. Coetzee,et al.  Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. , 2000, Human molecular genetics.

[4]  G. Coetzee,et al.  Multiple Signal Input and Output Domains of the 160-Kilodalton Nuclear Receptor Coactivator Proteins , 1999, Molecular and Cellular Biology.

[5]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[6]  I. Irminger-Finger,et al.  The Functions of Breast Cancer Susceptibility Gene 1 (BRCA1) Product and Its Associated Proteins , 1999, Biological chemistry.

[7]  M. Stallcup,et al.  GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Wilson,et al.  Characterization and expression of a cDNA encoding the human androgen receptor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M. Stratton,et al.  The genetics of breast cancer susceptibility. , 1998, Annual review of genetics.

[10]  D. Livingston,et al.  BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. , 1999, Cancer research.

[11]  N. Sedransk,et al.  Combined androgen and antimetabolite therapy of advanced female breast cancer A report of the cooperative breast cancer group , 1975, Cancer.

[12]  R. Young,et al.  BRCA1 is a component of the RNA polymerase II holoenzyme. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Erdos,et al.  BRCA1 inhibition of estrogen receptor signaling in transfected cells. , 1999, Science.

[14]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[15]  M B Daly,et al.  Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. , 1999, American journal of human genetics.

[16]  J. Bringer,et al.  Male breast cancer and the androgen receptor gene , 1993, Nature genetics.

[17]  D. Aswad,et al.  Regulation of transcription by a protein methyltransferase. , 1999, Science.

[18]  K. Schulz,et al.  Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[19]  C. Glass,et al.  Coactivator and corepressor complexes in nuclear receptor function. , 1999, Current opinion in genetics & development.

[20]  M. Gleave,et al.  Differential transactivation by the androgen receptor in prostate cancer cells , 1998, The Prostate.